The antibody response induced by active immunotherapies can be engineered to specifically target pathological Aβ, Tau, and αSyn and could facilitate the natural antibody response observed in patients with AD or PD against those pathological targets, especially since naturally occurring autoantibodies do not seem to be produced at therapeutic concentrations [71,72]. This evidence concerns the gene MAPT and Alzheimer disease.